

oasmia

NAVENTUS LIFE SCIENCES SUMMIT

F.R. Martelet, M.D., CEO

29th September 2021



Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.


FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Building a sustainable global oncology business



Approved product & growing pipeline focused on **hard-to-treat** and **late-stage cancers** with limited treatment options



Strong in-house capabilities including **regulatory, development & global partnering** relationships



Portfolio expansion strategy targeting **multiple oncology MoAs** through in-licensing & M&A



New leadership team, strategy & focus since March 2020

Our areas of focus



Oncology R&D: in-licensed & wholly-owned development-stage assets:

- Cantrixil
- Docetaxel Micellar
- Strategic pipeline development



Commercial: revenues from out-licensed products and technologies:

- Apealea®
- XR-17™/ XR-18 / XR-19
- Animal health assets (for partnering)



Oncology R&D: emerging portfolio ready for further expansion

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography	
Human Health Portfolio									
Cantrixil	Ovarian cancer							Global	
Docetaxel micellar	Prostate cancer							EU/EAA	
Animal Health Portfolio (Canines)									
Paccal vet (paclitaxel)	Mammary Carcinoma							USA	
Doxophos vet (doxorubicin)	Lymphoma							USA	

Oncology Commercial: targeting revenues from out-licensed products & technologies

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography
---------	------------	--------------	---------	---------	---------	-------------------------	-------------------	-----------

Human Health Portfolio

Apealea® / Paclical® (paclitaxel)	Ovarian cancer						EU / EEA	
	Ovarian cancer						USA	


Project	Objective	Discovery	Feasibility	Development	Validation	Launch
XR-17™	Solubilization platform					
XR-18	Next generation of XR-17					Target 2023
XR-19	Solubilization platform – dual encapsulation				Target 2022	

Collaboration with the Karolinska Institutet to further explore the biological potential of XR-17™

Transformed leadership with broad industry experience




A revamped strategy to drive expansion 2021 – 2023




The 'string of pearls' approach to build critical mass

- Leveraging our **Development, Regulatory & Commercial Partnering** skills
- Evaluating a wide range of **targets with multiple MoA** (pre-clinical to late Phase 3)
- Potential for **high value exit opportunities** from Phase 2



Mid-stage oncology assets are key industry value drivers

Cancer company buyouts - combined value (\$m)



Source: EvaluatePharma

*“A dissection of five years' biopharma buyout spending reveals that **most deals are struck over preclinical and mid-stage assets**, while buyers remain **most interested in cancer and neurological disorders.**”*
Amy Brown, EvaluatePharma

Cantrixil – Phase 2 in ovarian cancer to start in H2-2022

- Global rights to first-in-class Cantrixil licensed from Kazia Therapeutics Limited (ASX:KZA) March 2021
- Targeting ovarian cancer – an area of unmet need with 314k new cases and 207k deaths worldwide in 2020*
- Tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to standard chemotherapies
 - Potential to improve outcome in relapsed ovarian cancer
 - Favorable safety and PK profiles in I.P. use
- Orphan drug designation from US FDA
- Strong patent protection to 2035

Next steps:

- Clinical Advisory Board set up and meeting convened
- Initiation of interactions with FDA & EMA to validate Phase 2 trial design for 2022 initiation
- Securing study drug supply

Docetaxel micellar – Phase 1b in prostate cancer underway

- Phase 1b trial initiated by SAKK - Swiss Group for Clinical Cancer Research
 - Open-label, multicenter, single-stage trial at major hospitals in Switzerland
 - Recruiting 18 chemotherapy-naïve patients with metastatic castration resistant prostate cancer (mCRPC) with adequate bone marrow, liver and renal function
- Docetaxel approved for wide range of solid malignancies
 - Standard of care for advanced prostate cancer
 - Docetaxel micellar uses XR-17™ to enable IV administration of docetaxel without solubility enhancers



*The global burden of prostate cancer*¹



In 2018 it was the 5th
leading cause of death in men worldwide



Cases are predicted to almost double from
approximately **1,275,000** per year by **2040**

Apealea® – global licensing deal & European approval in ovarian cancer

Approved in EU for treatment of first relapse ovarian cancer¹

Targeting patients unable to tolerate solvent-based paclitaxel

Solvent-free IV formulation of paclitaxel

- No polyoxyethylated castor oil or dehydrated alcohol
- No glucocorticosteroids required pre-medication
- Shorter infusion and overall ‘chair’ time






apealea®
paclitaxel (micellar)

Taxol®


Abraxane®
nanoparticle albumin bound paclitaxel

Lipusu®

Genexol-PM®
Korea

Company	 oasmia	 Bristol Myers Squibb™	 Celgene	 LUYE PHARMA	 samyang Biopharm
Indication	Ovarian Cancer	Ovarian Cancer Breast Cancer NSCLC	Breast Cancer	Ovarian Cancer Breast Cancer NSCLC	Ovarian Cancer Breast Cancer NSCLC
Infusion Solution	Micellar Solution	Emulsion	Colloidal Suspension	Liposome	Micellar Solution
Particle Size	25nm	10-22nm	130nm	400nm	~25nm
Excipient	XR-17™	Cremophor EL	Human Albumin	Lecithin/Cholesterol	PEG-PDLLA
Dose	250mg/m ²	175mg/m ²	260mg/m ²	175mg/m ²	260mg/m ²
Ratio (Excipient : API)	1.3:1.0	88.0:1.0	9.0:1.0	-	5.0:1.0
Infusion Time	1h	3h	<1h	3h	0.5h
Pre-medication	Not mandatory	Yes	No	Yes	No
Hypersensitivity	No	Yes	No	Yes	No

Apealea® – out licensed to Elevar and its partners



Global commercialization agreement with US-based Elevar Therapeutics, a subsidiary of South Korea's HLB, worth up to \$698m + royalties (incl. \$20m upfront)

Apealea® - Elevar planning a US IND filing in Q1 2022





- Elevar has developed a comprehensive plan to support NDA
- Partnership with Gynecologic Oncology Group (GOG) Foundation to develop clinical registrational study concept
- Current intention to seek FDA feedback by Q1 2022 prior to initiating clinical studies, including the PK plan and registrational trial

Q2 Financial results

- Net sales of 4.6 MSEK
 - Vials shipped to Elevar Canada for PK study
- Operating costs totalled MSEK 32
 - Confirming annualized cost savings of approx. MSEK 100
- Operating cashflow of MSEK -41
 - Confirming "cash burn" year to date at around MSEK 12 per month
- Cash and cash equivalents amounted to MSEK 176 at the end of the quarter

Significant reduction in Opex (MSEK)



Looking ahead – multiple catalysts to drive value in 2022

Potential near- and mid-term value drivers

- **Sustained M&A & in-licensing to build critical mass in oncology**
- Cantrixil – initiation of Phase 2
- Docetaxel micellar – Phase 1b completion
- Apealea® – initiation of additional US pivotal studies by Elevar; partnering in key territories; potential for initial royalties
- XR-17™ technology platform – enhancement
- Animal Health assets – divestment or partnering agreements

Building a sustainable global oncology business

- **String of pearls strategy** – creating an oncology pipeline with multiple shots on goal
- Becoming a **global oncology partner** – broad capabilities to maximize M&A and in-licensing opportunities
- Focus on **mid-stage value drivers** – Cantrixil progressing rapidly
- **Revenues** from Apealea & delivery technologies